drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB09038 | DB11978 | 1,450 | 124 | [
"DDInter636",
"DDInter822"
] | Empagliflozin | Glasdegib | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1450,
24,
124
]
],
[
[
1450,
24,
466
],
[
466,
62,
124
]
],
[
[
1450,
63,
739
],
[
739,
24,
124
]
],
[
[
1450,
24,
1612
],
[
1612,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin a... |
DB00054 | DB09068 | 1,432 | 1,427 | [
"DDInter6",
"DDInter1948"
] | Abciximab | Vortioxetine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1432,
24,
1427
]
],
[
[
1432,
64,
25
],
[
25,
24,
1427
]
],
[
[
1432,
25,
256
],
[
256,
24,
1427
]
],
[
[
1432,
24,
477
],
[
477,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistrep... | Abciximab may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Abciximab may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderate in... |
DB00384 | DB11130 | 1,275 | 407 | [
"DDInter1859",
"DDInter1344"
] | Triamterene | Opium | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1275,
24,
407
]
],
[
[
1275,
24,
104
],
[
104,
24,
407
]
],
[
[
1275,
63,
352
],
[
352,
24,
407
]
],
[
[
1275,
1,
706
],
[
706,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospiu... |
DB00373 | DB00902 | 461 | 104 | [
"DDInter1809",
"DDInter1168"
] | Timolol | Methdilazine | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
461,
24,
104
]
],
[
[
461,
24,
820
],
[
820,
1,
104
]
],
[
[
461,
24,
401
],
[
401,
63,
104
]
],
[
[
461,
23,
286
],
[
286,
62,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that cou... |
DB00987 | DB10276 | 1,224 | 1,624 | [
"DDInter460",
"DDInter1623"
] | Cytarabine | Rotavirus vaccine | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1224,
25,
1624
]
],
[
[
1224,
63,
552
],
[
552,
25,
1624
]
],
[
[
1224,
24,
1307
],
[
1307,
25,
1624
]
],
[
[
1224,
37,
770
],
[
770,
... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Car... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may l... |
DB00359 | DB00912 | 161 | 473 | [
"DDInter1721",
"DDInter1581"
] | Sulfadiazine | Repaglinide | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
161,
24,
473
]
],
[
[
161,
6,
3486
],
[
3486,
45,
473
]
],
[
[
161,
21,
28873
],
[
28873,
60,
473
]
],
[
[
161,
24,
1512
],
[
1512,
... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compou... | Sulfadiazine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Sulfadiazine (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Diclo... |
DB00775 | DB09079 | 1,226 | 1,496 | [
"DDInter1818",
"DDInter1296"
] | Tirofiban | Nintedanib | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
1226,
24,
1496
]
],
[
[
1226,
25,
707
],
[
707,
24,
1496
]
],
[
[
1226,
64,
20
],
[
20,
24,
1496
]
],
[
[
1226,
24,
477
],
[
477,
... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",... | Tirofiban may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Tirofiban may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate in... |
DB09472 | DB11986 | 1,383 | 484 | [
"DDInter1693",
"DDInter648"
] | Sodium sulfate | Entrectinib | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1383,
24,
484
]
],
[
[
1383,
63,
222
],
[
222,
23,
484
]
],
[
[
1383,
63,
774
],
[
774,
24,
484
]
],
[
[
1383,
24,
180
],
[
180,
... | [
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]... | Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Degarelix an... |
DB00515 | DB06273 | 589 | 980 | [
"DDInter387",
"DDInter1824"
] | Cisplatin | Tocilizumab | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
589,
24,
980
]
],
[
[
589,
63,
1461
],
[
1461,
23,
980
]
],
[
[
589,
63,
494
],
[
494,
24,
980
]
],
[
[
589,
24,
309
],
[
309,
2... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyram... |
DB00397 | DB01168 | 1,466 | 1,053 | [
"DDInter1458",
"DDInter1526"
] | Phenylpropanolamine | Procarbazine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1466,
25,
1053
]
],
[
[
1466,
21,
28898
],
[
28898,
60,
1053
]
],
[
[
1466,
63,
1000
],
[
1000,
24,
1053
]
],
[
[
1466,
24,
480
],
[
4... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effe... | Phenylpropanolamine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Procarbazine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases... |
DB00106 | DB06663 | 618 | 1,154 | [
"DDInter4",
"DDInter1398"
] | Abarelix | Pasireotide | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
618,
25,
1154
]
],
[
[
618,
23,
112
],
[
112,
23,
1154
]
],
[
[
618,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
618,
24,
480
],
[
480,
... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and ... |
DB06650 | DB10315 | 1,500 | 1,137 | [
"DDInter1324",
"DDInter1127"
] | Ofatumumab | Measles virus vaccine live attenuated | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1500,
25,
1137
]
],
[
[
1500,
64,
581
],
[
581,
25,
1137
]
],
[
[
1500,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
1500,
25,
676
],
[
676,
... | [
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Ofatumumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra ma... |
DB00401 | DB08912 | 84 | 1,040 | [
"DDInter1298",
"DDInter462"
] | Nisoldipine | Dabrafenib | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
84,
24,
1040
]
],
[
[
84,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
84,
7,
10439
],
[
10439,
46,
1040
]
],
[
[
84,
18,
2183
],
[
2183,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Nisoldipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Nisoldipine (Compound) upregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Dabrafenib (Compound)
Nisoldipine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Dabrafenib (Compound)
Nisoldipine (... |
DB00976 | DB01190 | 1,056 | 568 | [
"DDInter1758",
"DDInter398"
] | Telithromycin | Clindamycin | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
1056,
24,
568
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
568
]
],
[
[
1056,
21,
29180
],
[
29180,
60,
568
]
],
[
[
1056,
35,
609
],
[
609,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Telithromycin (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Clindamycin (Compound)
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin m... |
DB08820 | DB12095 | 1,478 | 179 | [
"DDInter997",
"DDInter1760"
] | Ivacaftor | Telotristat ethyl | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1478,
24,
179
]
],
[
[
1478,
63,
1601
],
[
1601,
24,
179
]
],
[
[
1478,
64,
1493
],
[
1493,
24,
179
]
],
[
[
1478,
24,
214
],
[
214,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
],
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivacaftor may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine m... |
DB00594 | DB06822 | 863 | 802 | [
"DDInter68",
"DDInter1812"
] | Amiloride | Tinzaparin | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
863,
24,
802
]
],
[
[
863,
24,
222
],
[
222,
24,
802
]
],
[
[
863,
24,
885
],
[
885,
25,
802
]
],
[
[
863,
63,
1512
],
[
1512,
2... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epop... |
DB00282 | DB09134 | 641 | 1,552 | [
"DDInter1383",
"DDInter966"
] | Pamidronic acid | Ioversol | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
641,
25,
1552
]
],
[
[
641,
24,
848
],
[
848,
25,
1552
]
],
[
[
641,
1,
963
],
[
963,
25,
1552
]
],
[
[
641,
25,
629
],
[
629,
2... | [
[
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibu... | Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol
Pamidronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may lead to a major life threatening inter... |
DB04844 | DB06788 | 843 | 1,616 | [
"DDInter1778",
"DDInter864"
] | Tetrabenazine | Histrelin | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
843,
24,
1616
]
],
[
[
843,
62,
112
],
[
112,
23,
1616
]
],
[
[
843,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
843,
63,
77
],
[
77,
... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Tetrabenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and... |
DB01215 | DB08820 | 1,418 | 1,478 | [
"DDInter677",
"DDInter997"
] | Estazolam | Ivacaftor | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1418,
24,
1478
]
],
[
[
1418,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1418,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
1418,
24,
1040
],
[
1... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Estazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Estazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Estazolam (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib ... |
DB00001 | DB06779 | 1,578 | 365 | [
"DDInter1037",
"DDInter470"
] | Lepirudin | Dalteparin | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
1578,
25,
365
]
],
[
[
1578,
23,
539
],
[
539,
62,
365
]
],
[
[
1578,
24,
1496
],
[
1496,
63,
365
]
],
[
[
1578,
24,
1100
],
[
1100,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may c... |
DB01238 | DB11979 | 673 | 1,320 | [
"DDInter118",
"DDInter625"
] | Aripiprazole | Elagolix | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
673,
24,
1320
]
],
[
[
673,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
673,
63,
79
],
[
79,
24,
1320
]
],
[
[
673,
24,
877
],
[
877,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and S... |
DB00445 | DB01299 | 322 | 698 | [
"DDInter655",
"DDInter1722"
] | Epirubicin | Sulfadoxine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
322,
24,
698
]
],
[
[
322,
23,
1247
],
[
1247,
40,
698
]
],
[
[
322,
63,
161
],
[
161,
1,
698
]
],
[
[
322,
7,
2216
],
[
2216,
4... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfado... |
DB00175 | DB00352 | 681 | 482 | [
"DDInter1509",
"DDInter1814"
] | Pravastatin | Tioguanine | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
681,
24,
482
]
],
[
[
681,
21,
28658
],
[
28658,
60,
482
]
],
[
[
681,
24,
1439
],
[
1439,
63,
482
]
],
[
[
681,
25,
1668
],
[
1668,
... | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Pravastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caus... | Pravastatin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Tioguanine (Compound)
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguan... |
DB00283 | DB00347 | 701 | 917 | [
"DDInter395",
"DDInter1871"
] | Clemastine | Trimethadione | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Moderate | 1 | [
[
[
701,
24,
917
]
],
[
[
701,
6,
8374
],
[
8374,
45,
917
]
],
[
[
701,
21,
28769
],
[
28769,
60,
917
]
],
[
[
701,
24,
401
],
[
401,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethadione"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trimethadione (Compound)
Clemastine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Trimethadione (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB05679 | DB11793 | 1,683 | 738 | [
"DDInter1907",
"DDInter1297"
] | Ustekinumab | Niraparib | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1683,
24,
738
]
],
[
[
1683,
63,
1213
],
[
1213,
24,
738
]
],
[
[
1683,
24,
496
],
[
496,
24,
738
]
],
[
[
1683,
24,
1619
],
[
1619,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine an... |
DB00366 | DB04946 | 1,594 | 924 | [
"DDInter600",
"DDInter907"
] | Doxylamine | Iloperidone | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1594,
24,
924
]
],
[
[
1594,
24,
1664
],
[
1664,
1,
924
]
],
[
[
1594,
24,
519
],
[
519,
40,
924
]
],
[
[
1594,
6,
10104
],
[
10104,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Co... |
DB00745 | DB01129 | 307 | 379 | [
"DDInter1236",
"DDInter1559"
] | Modafinil | Rabeprazole | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
307,
24,
379
]
],
[
[
307,
63,
660
],
[
660,
1,
379
]
],
[
[
307,
6,
8374
],
[
8374,
45,
379
]
],
[
[
307,
21,
29232
],
[
29232,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
... | Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (Compound)
Modafinil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rabeprazole (Compound)
Modafinil (Compound) causes Urticaria (Side Effect) and Urtica... |
DB01138 | DB06589 | 804 | 1,250 | [
"DDInter1726",
"DDInter1400"
] | Sulfinpyrazone | Pazopanib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
804,
24,
1250
]
],
[
[
804,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
804,
24,
1135
],
[
1135,
62,
1250
]
],
[
[
804,
24,
1151
],
[
1151,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Comp... | Sulfinpyrazone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Sulfinpyrazone m... |
DB01050 | DB01155 | 848 | 872 | [
"DDInter900",
"DDInter813"
] | Ibuprofen | Gemifloxacin | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Moderate | 1 | [
[
[
848,
24,
872
]
],
[
[
848,
63,
739
],
[
739,
1,
872
]
],
[
[
848,
24,
956
],
[
956,
1,
872
]
],
[
[
848,
24,
945
],
[
945,
40,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin (Compound) resembles Gemifloxacin (Co... |
DB00808 | DB00860 | 1,605 | 891 | [
"DDInter916",
"DDInter1513"
] | Indapamide | Prednisolone | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1605,
24,
891
]
],
[
[
1605,
63,
175
],
[
175,
40,
891
]
],
[
[
1605,
63,
167
],
[
167,
1,
891
]
],
[
[
1605,
24,
1220
],
[
1220,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predni... |
DB00261 | DB00364 | 702 | 417 | [
"DDInter93",
"DDInter1717"
] | Anagrelide | Sucralfate | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a _cytoprotective agent_, protec... | Minor | 0 | [
[
[
702,
23,
417
]
],
[
[
702,
21,
28882
],
[
28882,
60,
417
]
],
[
[
702,
25,
17
],
[
17,
62,
417
]
],
[
[
702,
24,
1512
],
[
1512,
... | [
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
... | Anagrelide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sucralfate (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken w... |
DB00431 | DB00850 | 1,503 | 1,630 | [
"DDInter1072",
"DDInter1432"
] | Lindane | Perphenazine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1503,
24,
1630
]
],
[
[
1503,
24,
827
],
[
827,
40,
1630
]
],
[
[
1503,
63,
508
],
[
508,
40,
1630
]
],
[
[
1503,
21,
29232
],
[
29232... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
"... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Perphenazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Perphenazine (Compound)
Lindan... |
DB11817 | DB14811 | 1,259 | 385 | [
"DDInter165",
"DDInter979"
] | Baricitinib | Isatuximab | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Major | 2 | [
[
[
1259,
25,
385
]
],
[
[
1259,
64,
1362
],
[
1362,
24,
385
]
],
[
[
1259,
63,
810
],
[
810,
24,
385
]
],
[
[
1259,
25,
270
],
[
270,
... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may... | Baricitinib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium... |
DB11828 | DB12457 | 1,406 | 1,180 | [
"DDInter1281",
"DDInter1598"
] | Neratinib | Rimegepant | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
1406,
24,
1180
]
],
[
[
1406,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
1406,
64,
1419
],
[
1419,
24,
1180
]
],
[
[
1406,
25,
283
],
[
283... | [
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Neratinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a modera... |
DB00758 | DB00802 | 1,347 | 1,322 | [
"DDInter413",
"DDInter43"
] | Clopidogrel | Alfentanil | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Moderate | 1 | [
[
[
1347,
24,
1322
]
],
[
[
1347,
24,
411
],
[
411,
1,
1322
]
],
[
[
1347,
63,
1454
],
[
1454,
1,
1322
]
],
[
[
1347,
6,
7524
],
[
7524,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
],
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Alfentanil (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil and Sufentanil (Compound) resembles Alfentanil (Comp... |
DB01177 | DB12010 | 77 | 214 | [
"DDInter904",
"DDInter785"
] | Idarubicin | Fostamatinib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
77,
24,
214
]
],
[
[
77,
25,
976
],
[
976,
24,
214
]
],
[
[
77,
74,
51
],
[
51,
24,
214
]
],
[
[
77,
63,
1005
],
[
1005,
24,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacit... | Idarubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerba... |
DB00252 | DB00364 | 362 | 417 | [
"DDInter1460",
"DDInter1717"
] | Phenytoin | Sucralfate | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a _cytoprotective agent_, protec... | Moderate | 1 | [
[
[
362,
24,
417
]
],
[
[
362,
6,
1829
],
[
1829,
45,
417
]
],
[
[
362,
21,
28882
],
[
28882,
60,
417
]
],
[
[
362,
24,
820
],
[
820,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"... | Phenytoin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Sucralfate (Compound)
Phenytoin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sucralfate (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken... |
DB00201 | DB00969 | 1,684 | 2 | [
"DDInter263",
"DDInter52"
] | Caffeine | Alosetron | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Moderate | 1 | [
[
[
1684,
24,
2
]
],
[
[
1684,
6,
6017
],
[
6017,
45,
2
]
],
[
[
1684,
21,
28883
],
[
28883,
60,
2
]
],
[
[
1684,
24,
1362
],
[
1362,
... | [
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Caffeine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alosetron (Compound)
Caffeine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Alosetron (Compound)
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapar... |
DB01097 | DB14409 | 1,377 | 1,129 | [
"DDInter1033",
"DDInter867"
] | Leflunomide | Human adenovirus e serotype 4 strain cl-68578 antigen | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1377,
24,
1129
]
],
[
[
1377,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1377,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
1377,
25,
676
],
[
676... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Leflunomide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Leflunomide may lead to a major life threatening interaction when taken with Usteki... |
DB00370 | DB00738 | 1,251 | 485 | [
"DDInter1230",
"DDInter1420"
] | Mirtazapine | Pentamidine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1251,
24,
485
]
],
[
[
1251,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1251,
18,
10699
],
[
10699,
57,
485
]
],
[
[
1251,
21,
29097
],
[
2... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Mirtazapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Mirtazapine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Pentamidine (Compound)
Mirtazapine (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Pentamidine (Compou... |
DB00491 | DB01124 | 127 | 1,411 | [
"DDInter1217",
"DDInter1828"
] | Miglitol | Tolbutamide | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
127,
24,
1411
]
],
[
[
127,
24,
959
],
[
959,
40,
1411
]
],
[
[
127,
63,
245
],
[
245,
40,
1411
]
],
[
[
127,
5,
11640
],
[
11640,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Mi... |
DB00731 | DB14723 | 1,144 | 159 | [
"DDInter1269",
"DDInter1026"
] | Nateglinide | Larotrectinib | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1144,
24,
159
]
],
[
[
1144,
24,
222
],
[
222,
23,
159
]
],
[
[
1144,
63,
1230
],
[
1230,
23,
159
]
],
[
[
1144,
24,
1375
],
[
1375,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and C... |
DB00675 | DB08886 | 888 | 637 | [
"DDInter1744",
"DDInter126"
] | Tamoxifen | Asparaginase Erwinia chrysanthemi | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
888,
24,
637
]
],
[
[
888,
24,
392
],
[
392,
24,
637
]
],
[
[
888,
64,
1668
],
[
1668,
24,
637
]
],
[
[
888,
25,
1387
],
[
1387,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapati... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Tamoxifen may lead to a major life threatening interaction when taken with Lenalidomide and ... |
DB01075 | DB01100 | 1,376 | 1,568 | [
"DDInter569",
"DDInter1470"
] | Diphenhydramine | Pimozide | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
1376,
24,
1568
]
],
[
[
1376,
63,
78
],
[
78,
40,
1568
]
],
[
[
1376,
6,
10215
],
[
10215,
45,
1568
]
],
[
[
1376,
21,
28766
],
[
2876... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Diphenhydramine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Pimozide (Compound)
Diphenhydramine (Compound) causes Hypotension (Side Effect... |
DB00586 | DB06414 | 1,512 | 655 | [
"DDInter537",
"DDInter703"
] | Diclofenac | Etravirine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1512,
24,
655
]
],
[
[
1512,
6,
4973
],
[
4973,
45,
655
]
],
[
[
1512,
21,
28740
],
[
28740,
60,
655
]
],
[
[
1512,
23,
1194
],
[
1194... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Diclofenac (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Diclofenac (Compound) causes Disturbance in attention (Side Effect) and Disturbance in attention (Side Effect) is caused by Etravirine (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when take... |
DB00486 | DB00719 | 1,614 | 1,219 | [
"DDInter1253",
"DDInter149"
] | Nabilone | Azatadine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
1614,
24,
1219
]
],
[
[
1614,
63,
13
],
[
13,
24,
1219
]
],
[
[
1614,
24,
830
],
[
830,
1,
1219
]
],
[
[
1614,
24,
1405
],
[
1405,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and P... |
DB01149 | DB12130 | 851 | 1,017 | [
"DDInter1274",
"DDInter1094"
] | Nefazodone | Lorlatinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
851,
25,
1017
]
],
[
[
851,
63,
608
],
[
608,
23,
1017
]
],
[
[
851,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
851,
64,
175
],
[
175,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene m... |
DB00741 | DB09043 | 167 | 135 | [
"DDInter885",
"DDInter36"
] | Hydrocortisone | Albiglutide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
167,
24,
135
]
],
[
[
167,
63,
126
],
[
126,
23,
135
]
],
[
[
167,
24,
519
],
[
519,
24,
135
]
],
[
[
167,
63,
323
],
[
323,
24,... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and P... |
DB00166 | DB00731 | 333 | 1,144 | [
"DDInter1076",
"DDInter1269"
] | Lipoic acid | Nateglinide | A vitamin-like antioxidant. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Minor | 0 | [
[
[
333,
23,
1144
]
],
[
[
333,
23,
959
],
[
959,
63,
1144
]
],
[
[
333,
23,
245
],
[
245,
24,
1144
]
],
[
[
333,
23,
959
],
[
959,
... | [
[
[
"Lipoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nateglinide"
]
],
[
[
"Lipoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
],
[
... | Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepir... |
DB00554 | DB06754 | 1,027 | 707 | [
"DDInter1478",
"DDInter471"
] | Piroxicam | Danaparoid | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1027,
25,
707
]
],
[
[
1027,
24,
121
],
[
121,
24,
707
]
],
[
[
1027,
63,
1560
],
[
1560,
24,
707
]
],
[
[
1027,
24,
738
],
[
738,
... | [
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenflurami... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pe... |
DB00836 | DB14509 | 543 | 1,399 | [
"DDInter1088",
"DDInter1081"
] | Loperamide | Lithium carbonate | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
543,
24,
1399
]
],
[
[
543,
25,
1374
],
[
1374,
24,
1399
]
],
[
[
543,
24,
820
],
[
820,
24,
1399
]
],
[
[
543,
63,
1010
],
[
1010,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Ab... | Loperamide may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine... |
DB00443 | DB00968 | 251 | 1,551 | [
"DDInter195",
"DDInter1185"
] | Betamethasone | Methyldopa | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Moderate | 1 | [
[
[
251,
24,
1551
]
],
[
[
251,
23,
1148
],
[
1148,
40,
1551
]
],
[
[
251,
7,
1996
],
[
1996,
46,
1551
]
],
[
[
251,
18,
12821
],
[
12821,... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
... | Betamethasone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline (Compound) resembles Methyldopa (Compound)
Betamethasone (Compound) upregulates CASP2 (Gene) and CASP2 (Gene) is upregulated by Methyldopa (Compound)
Betamethasone (Compound) downregulates TRIB1 (Ge... |
DB00912 | DB01238 | 473 | 673 | [
"DDInter1581",
"DDInter118"
] | Repaglinide | Aripiprazole | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
473,
24,
673
]
],
[
[
473,
24,
851
],
[
851,
1,
673
]
],
[
[
473,
63,
1630
],
[
1630,
1,
673
]
],
[
[
473,
6,
8374
],
[
8374,
45... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (... |
DB00371 | DB01114 | 1,050 | 272 | [
"DDInter1154",
"DDInter362"
] | Meprobamate | Chlorpheniramine | A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1050,
24,
272
]
],
[
[
1050,
24,
849
],
[
849,
63,
272
]
],
[
[
1050,
24,
128
],
[
128,
24,
272
]
],
[
[
1050,
21,
28705
],
[
28705,
... | [
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenir... |
DB01041 | DB06589 | 770 | 1,250 | [
"DDInter1789",
"DDInter1400"
] | Thalidomide | Pazopanib | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
770,
25,
1250
]
],
[
[
770,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
770,
7,
6858
],
[
6858,
46,
1250
]
],
[
[
770,
18,
20113
],
[
20113,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Thalidomide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopa... | Thalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Thalidomide (Compound) upregulates LPL (Gene) and LPL (Gene) is upregulated by Pazopanib (Compound)
Thalidomide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Pazopanib (Compound)
Thalidomide (Compound)... |
DB00041 | DB00924 | 1,648 | 1,405 | [
"DDInter38",
"DDInter454"
] | Aldesleukin | Cyclobenzaprine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
1648,
24,
1405
]
],
[
[
1648,
24,
1302
],
[
1302,
1,
1405
]
],
[
[
1648,
24,
401
],
[
401,
63,
1405
]
],
[
[
1648,
24,
1264
],
[
1264,... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
]... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate inter... |
DB00277 | DB01359 | 1,031 | 729 | [
"DDInter1791",
"DDInter1417"
] | Theophylline | Penbutolol | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Major | 2 | [
[
[
1031,
25,
729
]
],
[
[
1031,
25,
461
],
[
461,
1,
729
]
],
[
[
1031,
25,
699
],
[
699,
40,
729
]
],
[
[
1031,
21,
28698
],
[
28698,
... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Penbutolol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (Co... | Theophylline may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Theophylline may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Theophylline (Compound) causes Insomni... |
DB01591 | DB08868 | 667 | 1,011 | [
"DDInter1696",
"DDInter737"
] | Solifenacin | Fingolimod | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
667,
25,
1011
]
],
[
[
667,
10,
11594
],
[
11594,
44,
1011
]
],
[
[
667,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
667,
21,
28792
],
[
2879... | [
[
[
"Solifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Solifenacin",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is trea... | Solifenacin (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound)
Solifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Solifenacin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal dis... |
DB00009 | DB15233 | 1,271 | 1,650 | [
"DDInter56",
"DDInter142"
] | Alteplase | Avapritinib | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1271,
25,
1650
]
],
[
[
1271,
24,
557
],
[
557,
24,
1650
]
],
[
[
1271,
24,
1512
],
[
1512,
25,
1650
]
],
[
[
1271,
25,
4
],
[
4,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxy... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac... |
DB00278 | DB04865 | 291 | 4 | [
"DDInter117",
"DDInter1335"
] | Argatroban | Omacetaxine mepesuccinate | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
291,
25,
4
]
],
[
[
291,
24,
738
],
[
738,
63,
4
]
],
[
[
291,
25,
39
],
[
39,
63,
4
]
],
[
[
291,
25,
1213
],
[
1213,
24,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Argatroban may lead to a major life threatening interaction when taken with Panobinostat and Panobi... |
DB00700 | DB11921 | 312 | 1,019 | [
"DDInter656",
"DDInter492"
] | Eplerenone | Deflazacort | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
312,
24,
1019
]
],
[
[
312,
40,
443
],
[
443,
24,
1019
]
],
[
[
312,
24,
629
],
[
629,
24,
1019
]
],
[
[
312,
1,
1561
],
[
1561,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Eplerenone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause ... | Eplerenone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction tha... |
DB11730 | DB13139 | 351 | 1,032 | [
"DDInter1588",
"DDInter1063"
] | Ribociclib | Levosalbutamol | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Major | 2 | [
[
[
351,
25,
1032
]
],
[
[
351,
63,
1573
],
[
1573,
23,
1032
]
],
[
[
351,
64,
1618
],
[
1618,
24,
1032
]
],
[
[
351,
25,
124
],
[
124,
... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Predni... | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Ribociclib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may ... |
DB00774 | DB09080 | 1,577 | 144 | [
"DDInter889",
"DDInter1331"
] | Hydroflumethiazide | Olodaterol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1577,
24,
144
]
],
[
[
1577,
40,
504
],
[
504,
24,
144
]
],
[
[
1577,
63,
11
],
[
11,
24,
144
]
],
[
[
1577,
25,
57
],
[
57,
24,... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazid... | Hydroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause... |
DB00889 | DB01128 | 1,133 | 918 | [
"DDInter840",
"DDInter204"
] | Granisetron | Bicalutamide | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1133,
24,
918
]
],
[
[
1133,
24,
129
],
[
129,
40,
918
]
],
[
[
1133,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1133,
21,
29666
],
[
29666,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Granisetron (Compound) causes Melaena (Side Effect) and ... |
DB00731 | DB09129 | 1,144 | 625 | [
"DDInter1269",
"DDInter373"
] | Nateglinide | Chromic chloride | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
1144,
24,
625
]
],
[
[
1144,
24,
170
],
[
170,
24,
625
]
],
[
[
1144,
24,
1385
],
[
1385,
63,
625
]
],
[
[
1144,
63,
1645
],
[
1645,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide... |
DB00092 | DB13915 | 58 | 689 | [
"DDInter40",
"DDInter146"
] | Alefacept | Axicabtagene ciloleucel | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Moderate | 1 | [
[
[
58,
24,
689
]
],
[
[
58,
63,
599
],
[
599,
24,
689
]
],
[
[
58,
24,
66
],
[
66,
24,
689
]
],
[
[
58,
25,
976
],
[
976,
25,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Efalizum... |
DB09074 | DB14962 | 1,362 | 1,363 | [
"DDInter1327",
"DDInter1847"
] | Olaparib | Trastuzumab deruxtecan | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Moderate | 1 | [
[
[
1362,
24,
1363
]
],
[
[
1362,
63,
1430
],
[
1430,
24,
1363
]
],
[
[
1362,
24,
810
],
[
810,
24,
1363
]
],
[
[
1362,
64,
384
],
[
384,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Strontium... |
DB00653 | DB09481 | 544 | 460 | [
"DDInter1120",
"DDInter1113"
] | Magnesium sulfate | Magnesium carbonate | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
544,
24,
460
]
],
[
[
544,
63,
355
],
[
355,
23,
460
]
],
[
[
544,
24,
1620
],
[
1620,
24,
460
]
],
[
[
544,
63,
1467
],
[
1467,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lact... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Te... |
DB08896 | DB11901 | 292 | 913 | [
"DDInter1576",
"DDInter107"
] | Regorafenib | Apalutamide | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
292,
24,
913
]
],
[
[
292,
64,
279
],
[
279,
24,
913
]
],
[
[
292,
63,
1237
],
[
1237,
24,
913
]
],
[
[
292,
24,
1627
],
[
1627,
... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
],
[
"Anisin... | Regorafenib may lead to a major life threatening interaction when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine m... |
DB06228 | DB06605 | 792 | 1,409 | [
"DDInter1609",
"DDInter108"
] | Rivaroxaban | Apixaban | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
792,
25,
1409
]
],
[
[
792,
6,
4973
],
[
4973,
45,
1409
]
],
[
[
792,
21,
29061
],
[
29061,
60,
1409
]
],
[
[
792,
23,
539
],
[
539,
... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Rivaroxaban",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"... | Rivaroxaban (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Apixaban (Compound)
Rivaroxaban (Compound) causes Gamma-glutamyltransferase increased (Side Effect) and Gamma-glutamyltransferase increased (Side Effect) is caused by Apixaban (Compound)
Rivaroxaban may cause a minor interaction that can limit clini... |
DB00765 | DB09112 | 1,266 | 1,455 | [
"DDInter1205",
"DDInter1306"
] | Metyrosine | Nitrous acid | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1266,
24,
1455
]
],
[
[
1266,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1266,
24,
433
],
[
433,
63,
1455
]
],
[
[
1266,
40,
1551
],
[
1551... | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin... |
DB00682 | DB01175 | 126 | 318 | [
"DDInter1951",
"DDInter672"
] | Warfarin | Escitalopram | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
126,
24,
318
]
],
[
[
126,
63,
1230
],
[
1230,
1,
318
]
],
[
[
126,
6,
8374
],
[
8374,
45,
318
]
],
[
[
126,
25,
86
],
[
86,
23,... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Warfarin may lead to a major life threatening interaction when tak... |
DB00619 | DB06688 | 1,419 | 1,430 | [
"DDInter909",
"DDInter1677"
] | Imatinib | Sipuleucel-T | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1419,
24,
1430
]
],
[
[
1419,
24,
175
],
[
175,
24,
1430
]
],
[
[
1419,
25,
676
],
[
676,
63,
1430
]
],
[
[
1419,
24,
310
],
[
310,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Imatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib ma... |
DB00414 | DB00554 | 590 | 1,027 | [
"DDInter16",
"DDInter1478"
] | Acetohexamide | Piroxicam | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Moderate | 1 | [
[
[
590,
24,
1027
]
],
[
[
590,
24,
1171
],
[
1171,
1,
1027
]
],
[
[
590,
24,
1559
],
[
1559,
62,
1027
]
],
[
[
590,
24,
752
],
[
752,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Piroxicam (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can l... |
DB00762 | DB00774 | 613 | 1,577 | [
"DDInter973",
"DDInter889"
] | Irinotecan | Hydroflumethiazide | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
613,
24,
1577
]
],
[
[
613,
24,
359
],
[
359,
40,
1577
]
],
[
[
613,
63,
323
],
[
323,
40,
1577
]
],
[
[
613,
24,
504
],
[
504,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound... |
DB00242 | DB01281 | 1,064 | 881 | [
"DDInter392",
"DDInter5"
] | Cladribine | Abatacept | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Major | 2 | [
[
[
1064,
25,
881
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
881
]
],
[
[
1064,
25,
4
],
[
4,
63,
881
]
],
[
[
1064,
24,
221
],
[
221,
6... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abatacept"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Abatacept
Cladribine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine... |
DB00857 | DB14881 | 1,387 | 180 | [
"DDInter1768",
"DDInter1329"
] | Terbinafine | Oliceridine | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
1387,
25,
180
]
],
[
[
1387,
24,
401
],
[
401,
24,
180
]
],
[
[
1387,
62,
752
],
[
752,
24,
180
]
],
[
[
1387,
64,
888
],
[
888,
... | [
[
[
"Terbinafine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Prome... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Terbinafine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and C... |
DB00218 | DB11057 | 1,176 | 720 | [
"DDInter1247",
"DDInter1223"
] | Moxifloxacin | Mineral oil | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1176,
24,
720
]
],
[
[
1176,
25,
927
],
[
927,
63,
720
]
],
[
[
1176,
25,
175
],
[
175,
24,
720
]
],
[
[
1176,
1,
956
],
[
956,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Enco... | Moxifloxacin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Moxifloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a ... |
DB00393 | DB09038 | 854 | 1,450 | [
"DDInter1295",
"DDInter636"
] | Nimodipine | Empagliflozin | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
854,
24,
1450
]
],
[
[
854,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
854,
24,
885
],
[
885,
24,
1450
]
],
[
[
854,
1,
84
],
[
84,
2... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol a... |
DB01115 | DB12141 | 336 | 971 | [
"DDInter1291",
"DDInter817"
] | Nifedipine | Gilteritinib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
336,
24,
971
]
],
[
[
336,
23,
1135
],
[
1135,
23,
971
]
],
[
[
336,
23,
466
],
[
466,
62,
971
]
],
[
[
336,
24,
820
],
[
820,
2... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Nifedipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutami... |
DB01452 | DB06282 | 993 | 516 | [
"DDInter532",
"DDInter1053"
] | Diamorphine | Levocetirizine | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
993,
24,
516
]
],
[
[
993,
63,
701
],
[
701,
24,
516
]
],
[
[
993,
24,
407
],
[
407,
63,
516
]
],
[
[
993,
1,
421
],
[
421,
24,
... | [
[
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium... |
DB00018 | DB00242 | 199 | 1,064 | [
"DDInter945",
"DDInter392"
] | Interferon alfa-n3 | Cladribine | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
199,
25,
1064
]
],
[
[
199,
23,
450
],
[
450,
64,
1064
]
],
[
[
199,
24,
270
],
[
270,
64,
1064
]
],
[
[
199,
24,
599
],
[
599,
... | [
[
[
"Interferon alfa-n3",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
... | Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may lead to a major life threatening interaction when taken with Cladribine
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizuma... |
DB06616 | DB11110 | 594 | 603 | [
"DDInter224",
"DDInter1115"
] | Bosutinib | Magnesium citrate | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
594,
24,
603
]
],
[
[
594,
64,
57
],
[
57,
24,
603
]
],
[
[
594,
63,
789
],
[
789,
24,
603
]
],
[
[
594,
24,
1616
],
[
1616,
24,... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Bosutinib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Fosca... |
DB00514 | DB04896 | 506 | 901 | [
"DDInter527",
"DDInter1220"
] | Dextromethorphan | Milnacipran | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
506,
25,
901
]
],
[
[
506,
25,
41
],
[
41,
1,
901
]
],
[
[
506,
6,
6112
],
[
6112,
45,
901
]
],
[
[
506,
18,
5901
],
[
5901,
57,... | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomil... | Dextromethorphan may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Dextromethorphan (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Milnacipran (Compound)
Dextromethorphan (Compound) downregulates GJA1 (Gene) and... |
DB00877 | DB08895 | 629 | 976 | [
"DDInter1678",
"DDInter1825"
] | Sirolimus | Tofacitinib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
629,
25,
976
]
],
[
[
629,
63,
307
],
[
307,
23,
976
]
],
[
[
629,
23,
1193
],
[
1193,
62,
976
]
],
[
[
629,
62,
1461
],
[
1461,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluc... |
DB00207 | DB00277 | 1,570 | 1,031 | [
"DDInter157",
"DDInter1791"
] | Azithromycin | Theophylline | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
1570,
24,
1031
]
],
[
[
1570,
6,
7950
],
[
7950,
45,
1031
]
],
[
[
1570,
21,
28698
],
[
28698,
60,
1031
]
],
[
[
1570,
24,
1096
],
[
1... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compo... | Azithromycin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Theophylline (Compound)
Azithromycin (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Theophylline (Compound)
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenoli... |
DB01320 | DB12001 | 651 | 564 | [
"DDInter783",
"DDInter7"
] | Fosphenytoin | Abemaciclib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
651,
25,
564
]
],
[
[
651,
25,
868
],
[
868,
24,
564
]
],
[
[
651,
63,
58
],
[
58,
24,
564
]
],
[
[
651,
64,
600
],
[
600,
24,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
... | Fosphenytoin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may c... |
DB01211 | DB06228 | 609 | 792 | [
"DDInter393",
"DDInter1609"
] | Clarithromycin | Rivaroxaban | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
609,
24,
792
]
],
[
[
609,
6,
4973
],
[
4973,
45,
792
]
],
[
[
609,
21,
28703
],
[
28703,
60,
792
]
],
[
[
609,
62,
307
],
[
307,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Comp... | Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound)
Clarithromycin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Modafinil a... |
DB00443 | DB11248 | 251 | 1,193 | [
"DDInter195",
"DDInter1965"
] | Betamethasone | Zinc gluconate | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
251,
23,
1193
]
],
[
[
251,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
251,
40,
167
],
[
167,
23,
1193
]
],
[
[
251,
24,
270
],
[
270,
... | [
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interac... |
DB00277 | DB00294 | 1,031 | 1,336 | [
"DDInter1791",
"DDInter701"
] | Theophylline | Etonogestrel | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Moderate | 1 | [
[
[
1031,
24,
1336
]
],
[
[
1031,
24,
566
],
[
566,
1,
1336
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
1336
]
],
[
[
1031,
21,
28900
],
[
28900... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
]... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Etonogestrel (Compound)
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etonogestrel (Compound)
Theophylline (Compound) causes Abdominal pain (Sid... |
DB00092 | DB01357 | 58 | 890 | [
"DDInter40",
"DDInter1160"
] | Alefacept | Mestranol | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
58,
24,
890
]
],
[
[
58,
24,
1197
],
[
1197,
40,
890
]
],
[
[
58,
24,
1486
],
[
1486,
24,
890
]
],
[
[
58,
24,
1583
],
[
1583,
6... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Mestranol (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate i... |
DB06688 | DB16582 | 1,430 | 899 | [
"DDInter1677",
"DDInter1080"
] | Sipuleucel-T | Lisocabtagene maraleucel | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Moderate | 1 | [
[
[
1430,
24,
899
]
],
[
[
1430,
63,
869
],
[
869,
24,
899
]
],
[
[
1430,
24,
1362
],
[
1362,
24,
899
]
],
[
[
1430,
24,
676
],
[
676,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Olapa... |
DB00328 | DB08895 | 831 | 976 | [
"DDInter921",
"DDInter1825"
] | Indomethacin | Tofacitinib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
831,
24,
976
]
],
[
[
831,
24,
1017
],
[
1017,
63,
976
]
],
[
[
831,
24,
723
],
[
723,
24,
976
]
],
[
[
831,
40,
24
],
[
24,
24,... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and A... |
DB00694 | DB00934 | 51 | 413 | [
"DDInter485",
"DDInter1124"
] | Daunorubicin | Maprotiline | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
51,
24,
413
]
],
[
[
51,
63,
1302
],
[
1302,
40,
413
]
],
[
[
51,
63,
847
],
[
847,
1,
413
]
],
[
[
51,
6,
4973
],
[
4973,
45,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotili... |
DB00434 | DB04908 | 13 | 1,671 | [
"DDInter459",
"DDInter741"
] | Cyproheptadine | Flibanserin | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
13,
24,
1671
]
],
[
[
13,
24,
830
],
[
830,
24,
1671
]
],
[
[
13,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
13,
24,
407
],
[
407,
63... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Doxylami... |
DB05239 | DB09034 | 866 | 1,313 | [
"DDInter425",
"DDInter1733"
] | Cobimetinib | Suvorexant | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
866,
24,
1313
]
],
[
[
866,
63,
1213
],
[
1213,
24,
1313
]
],
[
[
866,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
866,
24,
1250
],
[
1250,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB04953 | DB11760 | 495 | 119 | [
"DDInter708",
"DDInter1742"
] | Ezogabine | Talazoparib | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
495,
24,
119
]
],
[
[
495,
25,
985
],
[
985,
24,
119
]
],
[
[
495,
24,
971
],
[
971,
63,
119
]
],
[
[
495,
63,
888
],
[
888,
24,... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertini... | Ezogabine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may c... |
DB00059 | DB08860 | 1,560 | 788 | [
"DDInter1404",
"DDInter1479"
] | Pegaspargase | Pitavastatin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
1560,
24,
788
]
],
[
[
1560,
24,
671
],
[
671,
1,
788
]
],
[
[
1560,
24,
700
],
[
700,
40,
788
]
],
[
[
1560,
24,
126
],
[
126,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastat... |
DB00224 | DB09043 | 215 | 135 | [
"DDInter917",
"DDInter36"
] | Indinavir | Albiglutide | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
215,
24,
135
]
],
[
[
215,
24,
126
],
[
126,
23,
135
]
],
[
[
215,
25,
467
],
[
467,
23,
135
]
],
[
[
215,
24,
870
],
[
870,
24,... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Indinavir may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a min... |
DB00197 | DB00912 | 1,324 | 473 | [
"DDInter1881",
"DDInter1581"
] | Troglitazone | Repaglinide | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1324,
24,
473
]
],
[
[
1324,
62,
333
],
[
333,
23,
473
]
],
[
[
1324,
23,
1103
],
[
1103,
23,
473
]
],
[
[
1324,
24,
798
],
[
798,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],
... | Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Repaglinide
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcin... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.